Relationships between Serum Levels of Atazanavir and Renal Toxicity or Lithiasis
Table 3
Characteristics of patients who had renal failure at the end of the study compared to those who did not have renal failure.
Renal failure
Yes ()
No ()
value
OR (confidence interval) for renal failure/CI (at 95% level)
Gender (M/F) () (%)
9/3 (75.0/25.0)
44/18 (70.97/29.03)
0.930
a
Age (years)
51.17
45.3
0.034
1.074 (1.002–1.150)
Grouped BMI ()
24.8
24.3
0.73
a
HIV risk group () (%)
HTSX
7 (58.33)
18 (12.90)
0.049
3.42 (0.96–12.2)
Non-HTSX
5 (41.67)
44 (87.10)
Lithiasis before start/after end of study () (%)
3/7 (30/70)
10/47 (17.54/85.46)
0.358
a
Renal colic before start/after end of study () (%)
1/10 (9.09/90.91)
4/57 (6.56/93.44)
0.76
a
Crystalluria after onset of ATV () (%)
3/9 (25.0/75.0)
10/52 (16.13/83.87)
0.103
a
Stage C HIV (yes/no) () (%)
5/7 (41.67/58.33)
20/42
0.086
2.99 (0.8–10.9)
Diabetes mellitus (yes/no) () (%)
4/8 (33.33/66.67)
2/60 (3.23/96.77)
0.0001
15 (2.4–95.4)
HTA (yes/no) () (%)
5/7 (41.67/58.33)
5/57 (8.06/91.94)
0.002
8.14 (1.8–35.3)
Overall levels of ATV (µg/L)
1074
1237
0.55
a
Basal CD4 (cells/µL)
345
574.4
0.072
0.998 (0.995–1.000)
Basal viral load (Log10 copies/mL)
3.96
2.42
0.002
2.46 (1.37–4.40)
Basal Cl creatinine MDRD (mL/min/1.73 m2)
94.5
98.7
0.56
a
: number; CI: confidence interval; M/F: male/female; BMI: body mass index; HTSX: heterosexual; HTA: high blood pressure; MDRD: Modification of Diet in Renal Disease; a: odds ratio (OR) cannot be calculated for risk groups.
